IFNL3 and hepatocellular carcinoma: This difference may be attributed to higher serum interferon (IFN)-λ3 levels in patients receiving NAs, which can upregulate IFN-stimulated genes and inhibit HBsAg production in hepatoma cells (17, –, 19).